^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTPN1 overexpression

    i
    Other names: PTPN1, Protein Tyrosine Phosphatase Non-Receptor Type 1, Tyrosine-Protein Phosphatase Non-Receptor Type 1, Protein-Tyrosine Phosphatase 1B, PTP1B, Protein Tyrosine Phosphatase, Placental, PTP-1B
    Entrez ID:
    5770
    5ms
    PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer. (PubMed, Front Immunol)
    The cell counting kit-8 (CCK-8) assay was performed to examine the effects of PTPN1 level on the sensitivity of breast cancer cells to paclitaxel...Finally, our results demonstrated that PTPN1 was associated with immune infiltration and immune checkpoint gene expression in breast cancer. PTPN1 was overexpressed in multiple cancer types and correlated with the clinical outcome and tumor immunity, suggesting it could be a valuable potential prognostic and immunological biomarker for pan-cancer.
    Journal • IO biomarker • Pan tumor
    |
    PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)
    |
    PTPN1 overexpression
    |
    paclitaxel
    6ms
    Mometasone Furoate Inhibits the Progression of Head and Neck Squamous Cell Carcinoma via Regulating Protein Tyrosine Phosphatase Non-Receptor Type 11. (PubMed, Biomedicines)
    Finally, MF could attenuate the effects of increased cell viability and decreased cell apoptosis caused by PTPN11 overexpression, suggesting that MF can inhibit the progression of HNSCC by regulating PTPN11. MF targeted PTPN11, promoting cell cycle arrest and cell apoptosis, and consequently exerting effective anti-tumor activity.
    Journal
    |
    PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)
    |
    PTPN1 overexpression
    over1year
    Inhibition of PTPN21 has antitumor effects in glioma by restraining the EGFR/PI3K/AKT pathway. (PubMed, Toxicol Appl Pharmacol)
    The tumorigenic potential of PTPN21-silenced glioma cells in vivo was markedly compromised. In summary, this study demonstrates that silencing of PTPN21 produces remarkable anticancer effects in glioma by restraining the EGFR/PI3K/AKT pathway.
    Journal
    |
    PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
    |
    PTPN1 overexpression • PTPN2 mutation
    2years
    Ophiopogonin‑B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways. (PubMed, Mol Med Rep)
    In conclusion, OP‑B effectively inhibited the progression of HCC both in vivo and in vitro. These effects may depend on downregulating PTP1B expression, thereby inactivating the PI3K/AKT pathway and activating the AMPK pathway.
    Journal
    |
    PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    PTPN1 overexpression • CD31 expression